Overview
The goal of this clinical trial is to learn the efficacy and safety of fractional 1064-nm picosecond laser for facial skin tightening. The main questions it aims to answer are:
- Efficacy of fractional 1064-nm picosecond laser for facial skin efficacy including the changes in wrinkle, nasolabial fold, skin laxity, and skin elasticity
- The changes in texture and pore volume using Antera
- The changes in bioengineering assessment: melanin index, erythema index, sebum level
- Adverse events Participants will be treated with 3 sessions of fractional 1064-nm picosecond laser (full face 4 passes, vector lines 4 passes), spaced 4 weeks apart. Follow-up visits 1, 3, and 6 months after the last treatments.
Description
The efficacy and safety of fractional 1064-nm picosecond laser for facial skin tightening in participants aged 40 to 55 years, BMI < 25 kg/m2, and have mild to moderate facial laxity.
Eligibility
Inclusion Criteria:
- Aged 40-55 years
- BMI < 25 kg/m2
- Asian
- Mild to moderate facial skin laxity using quantitative grading scale (grade 1.5-2.5)
Exclusion Criteria:
- Pregnant or lactation
- Subjects who have been treated with any kind of energy-based device 6 months prior to the inclusion
- Subjects who have been injected with botulinum toxin, filler, or platelet-rich plasma on their faces 6 months prior to the inclusion
- Active skin infections
- History of hypertrophic scars or keloids